Polyclonal expansion of TCR Vbeta 21.3+ CD4+ and CD8+ T cells is a hallmark of Multisystem Inflammatory Syndrome in Children

Marion Moreews,Kenz Le Gouge,Samira Khaldi-Plassart,Rémi Pescarmona,Anne-Laure Mathieu,Christophe Malcus,Sophia Djebali,Alicia Bellomo,Olivier Dauwalder,Magali Perret,Marine Villard,Emilie Chopin,Isabelle Rouvet,Francois Vandenesh,Céline Dupieux,Robin Pouyau,Sonia Teyssedre,Margaux Guerder,Tiphaine Louazon,Anne Moulin-Zinsch,Marie Duperril,Hugues Patural,Lisa Giovannini-Chami,Aurélie Portefaix,Behrouz Kassai,Fabienne Venet,Guillaume Monneret,Christine Lombard,Hugues Flodrops,Jean-Marie De Guillebon,Fanny Bajolle,Valérie Launay,Paul Bastard,Shen-Ying Zhang,Valérie Dubois,Olivier Thaunat,Jean-Christophe Richard,Mehdi Mezidi,Omran Allatif,Kahina Saker,Marlène Dreux,Laurent Abel,Jean-Laurent Casanova,Jacqueline Marvel,Sophie Trouillet-Assant,David Klatzmann,Thierry Walzer,Encarnita Mariotti-Ferrandiz,Etienne Javouhey,Alexandre Belot
DOI: https://doi.org/10.1126/sciimmunol.abh1516
2021-05-25
Abstract:Multiple Inflammatory Syndrome in Children (MIS-C) is a delayed and severe complication of SARS-CoV-2 infection that strikes previously healthy children. As MIS-C combines clinical features of Kawasaki disease and Toxic Shock Syndrome (TSS), we aimed to compare the immunological profile of pediatric patients with these different conditions. We analyzed blood cytokine expression, and the T cell repertoire and phenotype in 36 MIS-C cases, which were compared to 16 KD, 58 TSS, and 42 COVID-19 cases. We observed an increase of serum inflammatory cytokines (IL-6, IL-10, IL-18, TNF-α, IFNγ, CD25s, MCP1, IL-1RA) in MIS-C, TSS and KD, contrasting with low expression of HLA-DR in monocytes. We detected a specific expansion of activated T cells expressing the Vβ21.3 T cell receptor β chain variable region in both CD4 and CD8 subsets in 75% of MIS-C patients and not in any patient with TSS, KD, or acute COVID-19; this correlated with the cytokine storm detected. The T cell repertoire returned to baseline within weeks after MIS-C resolution. Vβ21.3+ T cells from MIS-C patients expressed high levels of HLA-DR, CD38 and CX3CR1 but had weak responses to SARS-CoV-2 peptides in vitro. Consistently, the T cell expansion was not associated with specific classical HLA alleles. Thus, our data suggested that MIS-C is characterized by a polyclonal Vβ21.3 T cell expansion not directed against SARS-CoV-2 antigenic peptides, which is not seen in KD, TSS and acute COVID-19.
What problem does this paper attempt to address?